Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cassava Sciences Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Cassava Sciences Inc trades at $1.33 (market cap $63.04M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 71.2× Cassava Sciences Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | FLNA | |
|---|---|---|
Market Cap | $4.49B | $63.04M |
Sector | Health | Health |
52-Week High | $28.06 | $4.64 |
52-Week Low | $20.06 | $1.16 |
Enterprise Value | $3.69B | -$23.53M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FLNA trades at $1.31, up 6.5% today, with a bearish technical signal but recent quarterly earnings beats. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97 million in 2025, with negative cash flow from operations. Analyst consensus is bullish with 8 buy ratings out of 12, and recent news highlights business updates and scientific presentations.
The outlook is mixed: strong analyst support and clinical progress offer upside potential, but persistent losses, negative cash flow, and high financial risks pose significant challenges. Investors should weigh the speculative growth prospects against the substantial operational deficits and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
